Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Bob Walsh who wrote (1348)	5/17/1999 8:46:00 AM
From: Bob Walsh	Read Replies (1) \| Respond to of 1510

It looks like there is some initial panic over this news. I may be wrong, but I believe that this is the acceptance of what had been previously been suspected - that HAART usage would effect the outcome of the study. More complete analysis by those in the field is needed since I am no expert. REMUNE apparently still may a place in the treatment of HIV and it still has potential uses in the variety of other immune diseases. Regards, Bob

To: Bob Walsh who wrote (1348)	5/17/1999 11:26:00 AM
From: Alex Glavinos	Read Replies (1) \| Respond to of 1510

I don't believe the news was all that bad. Not enough end points not enough people died since HAART was used. More importantly is the following: >"analysis, showed significantly greater reduction in viral load (level of HIV RNA in plasma) after 48 and 96 weeks of treatment and significantly greater increases in lymphoctye proliferation in those who added REMUNE to their underlying anti-retroviral therapy, compared with those who did not."< This Verifies the Valentine and Thai studies. All is not lost and may be a good buying opportunity. Staying long and keeping the faith.